MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the geneType Multi-Risk Test.
The paper is coauthored by Professor John Hopper and Associate Professor Enes Makalic from the Centre for Epidemiology and Biostatistics, University of Melbourne, and GTG science team members, Dr Chi Kuen Wong, Dr Gillian Dite, Lawrence Whiting, Dr Nicholas Murphy and Dr Richard Allman.
The paper titled “Polygenic risk scores for cardiovascular diseases and type 2 diabetes” has been published in PLOS ONE https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278764.
Publication highlights:
The research team used a sophisticated sampling strategy that enabled the true performance of the polygenic risk score to be determined and not be influenced by the effects of age and sex.
Cardiovascular diseases and type 2 diabetes are leading and serious conditions in Australia. In 2018, more than 4 million Australians reported having a cardiovascular disease.1 In 2021, an estimated 571,000 Australians aged 18 and over had coronary artery disease, which was the single leading cause of death, resulting in 16,600 deaths.2 Atrial fibrillation is thought to affect approximately 2% of the Australian population, equivalent to more than 500,000 people.3
Type 2 diabetes is the seventh most common cause of death in Australia and almost 1.9 million Australians have diabetes, including 500,000 who are not yet diagnosed.4
Genetic Technologies’ CEO, Simon Morriss, said, “Implementation of risk assessment tests, such as our geneType Multi-Risk Test, that accurately predict the risk of a patient developing one of these serious diseases, will enable early intervention with great potential for improved patient outcomes”.
Authorised for release by the board of directors of Genetic Technologies Limited.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com
1https://www.heartfoundation.org.au/bundles/for-professionals/key-stats-cardiovascular-disease
2https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/heart-stroke-and-vascular-disease-and-subtypes/what-is-coronary-heart-disease#Common
3https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/atrial-fibrillation-in-australia/contents/how-many-australians-have-atrial-fibrillation
4https://www.diabetesaustralia.com.au/about-diabetes/diabetes-in-australia/
CONTACT: Enquiries: Investor Relations Adrian Mulcahy Market Eye – Automic Group M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au
Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…
GREENVILLE, SC / ACCESSWIRE / March 26, 2024 / Rymedi is proud to announce its…
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2…
Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…
Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…
Proven healthcare executive and life sciences strategist joins to bring groundbreaking BioFuse Multi-Tissue Welder (MTW)…